x
Sign up for the Weekly Roundup below.
|
|||||||||||||||||||||||||
|
GBI’s information products track and illuminate virtually every aspect of China’s pharmaceutical industry. From pipeline and competitor data to performance benchmarks to physician data to pricing and tendering analytical tools, GBI provides the intelligence industry relies on to conduct its business. READ MORE...
Whether conducting a China opportunity assessment for a pharmaceutical, executing due diligence on an acquisition target, or advising on a licensing or M&A transaction, GBI leverages a unique, data-driven and systematic approach to its consulting services. READ MORE...
 Sign up for GBI's Weekly Roundup to track the news and get our views on China's pharma industry.
|
|||||||||||||||||||||||||
 Friday, July 30, 2010
Thursday, July 29, 2010
  http://www.gbipharma.com/podcast/mp3/GBI_Andrew_webb_interview.mp3
This month, Senior Director of Personalized Healthcare Market Development at QIAGEN, Andrew Webb, sits down with GBI to discuss the exciting field of personalized medicine. In this interview, Andrew offers an insider look at new applications for molecular targeting, as well as the role this technology will play in pharmaceutical development in the future.
 http://www.gbipharma.com/podcast/mp3/GBI_Nisa_Leung_interview.mp3
In this interview, Nisa Leung, partner of Qiming Ventures, shares her insights into how the venture capital landscape for the healthcare area has changed over the years, successful strategies for deal sourcing, and future trends in China’s healthcare market.
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
